8-K: 2seventy bio Reports Preliminary Full-Year U.S. Abecma Sales and Select Financial Results

2seventy bio announces preliminary U.S. Abecma sales of $242 million for 2024 and targets quarterly breakeven by the end of 2025.

Summary

• 2seventy bio reported preliminary U.S. Abecma sales of $242 million for the full year 2024.
• Fourth quarter U.S. Abecma sales were approximately $59 million.
• The company had approximately $184 million in cash, cash equivalents, and marketable securities as of December 31, 2024.
• Net cash burn for the fourth quarter of 2024 was $9 million.
• 2seventy bio is aiming to achieve quarterly breakeven by the end of 2025.
• The company will provide further details on fourth quarter and full year 2024 results during its earnings call next month and in its Form 10-K, expected to be filed by March 17, 2025.
• 2seventy bio and Bristol Myers Squibb (BMS) share equally in all profits and losses related to the development, manufacturing, and commercialization of Abecma in the U.S.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company met its revenue guidance and is on track to achieve breakeven. However, there are risks associated with the treatment and the company's financial position.

Positives

• Abecma sales met previously issued guidance.
• The company is on track to achieve quarterly breakeven by the end of 2025.
• The Abecma-focused strategy is proving effective.
• The company has a substantial cash position.

Negatives

• Fourth quarter revenue was impacted by higher deferrals of infusions into 2025.
• Early deaths were observed in the ABECMA arm of the KarMMa-3 study, with a higher proportion of patients experiencing death within 9 months after randomization compared to the standard regimens arm.
• The company is still experiencing a cash burn, although it is decreasing.

Risks

• The company's accounting and management systems may not be prepared to meet the financial reporting requirements of operating as an independent public company.
• Abecma may not be as commercially successful as anticipated.
• The strategic realignment may not be as successful as anticipated and may cause disruptions.
• The company may be unable to manage operating expenses or cash use for operations.
• There are risks associated with Abecma treatment, including Cytokine Release Syndrome (CRS), neurologic toxicities, HLH/MAS, prolonged cytopenia, and secondary malignancies.

Future Outlook

2seventy bio expects the use of CAR-T in multiple myeloma to continue to grow and believes Abecma will continue to make a meaningful difference in the lives of patients. The company aims to achieve quarterly breakeven by the end of 2025.

Management Comments

• Chip Baird, chief executive officer, stated that the company is pleased to see Abecma expansion in the third line setting.
• Chip Baird noted that the Abecma-focused strategy has put the company on track to achieve quarterly breakeven later this year.

Industry Context

The announcement highlights the growing importance of CAR-T therapies in the treatment of multiple myeloma. Competition in this space remains high, but 2seventy bio believes Abecma will continue to be a significant player.

Comparison to Industry Standards

• Abecma competes with other BCMA-directed CAR-T therapies such as Carvykti (ciltacabtagene autoleucel) developed by Johnson & Johnson and Legend Biotech.
• The $242 million in U.S. sales for Abecma in 2024 provides a benchmark for comparing its market penetration against competitors.
• The target to achieve quarterly breakeven by the end of 2025 is a key indicator of 2seventy bio's financial health and operational efficiency compared to other biotech companies in the cell therapy space.

Stakeholder Impact

• Shareholders will be interested in the company's progress towards breakeven and the commercial success of Abecma.
• Patients with multiple myeloma benefit from the availability of Abecma as a treatment option.
• Employees are impacted by the company's strategic realignment and focus on Abecma.

Next Steps

• The company will provide further details on fourth quarter and full year 2024 results during its earnings call next month.
• The company expects to file its Form 10-K with the SEC by no later than March 17, 2025.

Key Dates

Keywords

Abecma, 2seventy bio, Bristol Myers Squibb, idecabtagene vicleucel, multiple myeloma, CAR-T therapy, sales results, financial results, breakeven, cash burn